BCL2 and ovarian cancer: In contrast, only 11% (3/28) of ovarian cancer sections had more than 50% of their stromal cells expressing Bcl-2 (Figure 5), and similar to extent of epithelial Bcl-2 staining, differences in extent of stromal Bcl-2 staining between tumor types were not statistically significant with the exception of PD samples having significantly less staining than both normal and cystadenoma samples (P = 0.1 and 0.03, respectively).